uploads/2018/12/SGMO-net-loss-1.png

How Are Sangamo Therapeutics’ Earnings and Expenses Trending?

By

Updated

Earnings trends

In the first nine months of 2018, Sangamo Therapeutics (SGMO) reported net income of -$49.7 million compared to -$41.5 million in the same period the prior year. The company reported EPS of -$0.52 in this period compared to -$0.55 in the first nine months of 2017. Wall Street analysts estimate that the company will report net income and EPS of -$68.63 million and -$0.73, respectively, in fiscal 2018.

In the third quarter, Sangamo Therapeutics reported net income and EPS of -$12.8 million and -$0.13, respectively, compared to -$12.4 million and -$0.15 in the third quarter of 2017.

Analysts estimate that the company is expected to report net income and EPS of -$17.47 and -$0.19, respectively, in the fourth quarter of 2018.

Article continues below advertisement

Peers’ performance

Sangamo Therapeutics’ peers in the biopharmaceuticals market, Spark Therapeutics (ONCE), Amicus Therapeutics (FOLD), and bluebird bio (BLUE) reported net income of -$47.36 million, -$159.2 million, and -$145.5 million, respectively, in the third quarter of 2018.

Expense trends

In the first nine months of 2018, Sangamo Therapeutics reported R&D (research and development) and G&A (general and administrative) expenses of $81.6 million and $32.4 million, respectively, compared to $46.4 million and $19.7 million in the same period the prior year.

In the third quarter, the company reported R&D and G&A expenditure of $28.8 million and $11.0 million, respectively, compared to $18.4 million and $6.4 million in the same period the prior year.

Wall Street analysts estimate that in the fourth quarter, Sangamo Therapeutics will report R&D and G&A expenses of $31.05 million and $12.73 million, respectively. Analysts also estimate that the company is expected to report R&D and G&A expenses of $112.18 million and $45.12 million, respectively, in fiscal 2018.

Advertisement

More From Market Realist